SCHEMBL2905503

SCHEMBL2905503

COc1ccc(C2(C(=O)Nc3cc4ccccc4c(Br)n3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 1/20 0.52
CACNA1H O95180 1/20 0.52
CACNA1I Q9P0X4 1/20 0.52
ALDH1A1 P00352 4/20 0.47
MAPK1 P28482 1/20 0.47
ELOVL1 Q9BW60 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.44
KDM4E B2RXH2 5/20 0.44
MAPT P10636 2/20 0.44
ADORA3 P0DMS8 2/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 3/20 0.41
HPGD P15428 2/20 0.41
P2RX7 Q99572 1/20 0.41
CFTR P13569 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15372165 0.88 LMNA (0.44) CACNA1GCACNA1HCACNA1IALDH1A1ELOVL1
SCHEMBL13840415 0.87 CACNA1G (0.38) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL4174047 0.84 CACNA1G (0.49) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL3044827 0.83 CACNA1G (0.48) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL2904146 0.82 HPGD (0.48) CACNA1GCACNA1HCACNA1IALDH1A1ELOVL1
SCHEMBL13804262 0.80 CACNA1G (0.48) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL2907880 0.80 CACNA1G (0.46) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL3147231 0.79 SIGMAR1 (0.47) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL2921648 0.79 CACNA1G (0.45) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL2926761 0.77 CACNA1G (0.45) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3012250-B1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2017-11-08 EP disclosed
EP-3012250-B1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2017-11-08 EP disclosed
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
EP-3012250-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2016-04-27 EP disclosed
EP-3012250-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2016-04-27 EP disclosed
EP-2578571-B1 Isoquinoline modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2015-09-16 EP disclosed
EP-2578571-B1 Isoquinoline modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2015-09-16 EP disclosed
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 US disclosed
US-8507524-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-13 US disclosed
EP-2578571-A1 Isoquinoline modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (US) 2013-04-10 EP disclosed
EP-2578571-A1 Isoquinoline modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (US) 2013-04-10 EP disclosed
CN-102743385-A Modulators of atp-binding cassette-transporters VERTEX PHARMA 2012-10-24 CN disclosed
EP-2217572-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2010-08-18 EP disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed
WO-2009064959-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-22 WO disclosed
WO-2009064959-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CACNA1G 2309/4885CACNA1H 2761/4885CACNA1I 2936/4885
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 CACNA1G 2301/4885CACNA1H 2791/4885CACNA1I 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.